Aquestive Therapeutics streamlines stockholder nomination rules in bylaw amendments

Aquestive Therapeutics, Inc. (Nasdaq: AQST) has adopted amended and restated bylaws that remove specific disclosure requirements for stockholders proposing candidates for the Board of Directors. The company's Board approved the changes on October 15, 2026, as part of a periodic review of corporate governance matters, with the new rules taking effect immediately. The Amended Bylaws supersede the company's previously existing Amended and Restated Bylaws.

The primary modification targets Article I, Section 11 of the prior bylaws, which governs stockholder nominations for board election. The amendments eliminate the requirement for a nominating stockholder to provide information regarding certain relationships between themselves or their associated persons and individuals acting in concert with the proposed nominee. This change also extends to removing information requirements concerning relationships with the nominee's immediate family, affiliates, and associates. Corresponding revisions were made to the definition of "Stockholder Associated Person" to exclude persons acting in concert with nominating stockholders or beneficial owners of Aquestive stock on whose behalf nominations or proposals are brought.

Aquestive Therapeutics is a Delaware corporation headquartered at 184 Liberty Corner Road, Suite 305, in Warren, New Jersey. The company's common stock, with a par value of $0.001 per share, trades on the Nasdaq Global Market under the symbol AQST. The filing does not indicate that Aquestive Therapeutics is an emerging growth company as defined by the Securities Act of 1933 or the Securities Exchange Act of 1934.

The full text of the Amended Bylaws is filed as Exhibit 3.1 to the Form 8-K current report. The company stated that the description of the amendments is qualified in its entirety by reference to this exhibit. In addition to the substantive changes to nomination procedures, the prior bylaws were amended to include technical, conforming, and non-substantive changes.

The Form 8-K report, dated October 15, 2026, was signed on October 19, 2026, by A. Ernest Toth, Jr., who serves as Chief Financial Officer for Aquestive Therapeutics. The filing was made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.